Method for inhibiting muscle protein proteolysis with antibodies to interleukin-6 receptor

• US 6,261,560 B1
• Filed: 08/13/1997
• Issued: 07/17/2001
• Est. Priority Date: 02/13/1995
• Status: Expired due to Fees

• Current Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Original Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Inventors: Fujita, Junya, Tsujinaka, Toshimasa, Ebisui, Chikara
• Primary Examiner(s): MERTZ, PREMA MARIA
• Application Number:
  US08/875,927
• Time in Patent Office: 1,434 Days
• Field of Search: 424/130.1, 424/139.1, 424/141.1, 424/142.1, 424/143.1, 424/145.1, 514/907, 514/921, 530/387.1, 530/387.9, 530/388.1, 530/388.22
• US Class Current: 424/143.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

The present invention provides a muscle protein proteolysis inhibiting agent comprising antibody to Interleukin-6 receptor (IL-6R antibody). Antibodies of animals other than humans such as mice and rats, chimeric antibodies of these antibodies with human antibodies, and reshaped human antibodies and so forth can be used for the IL-6R antibody. The muscle protein proteolysis inhibiting agent of the present invention is useful in the inhibition of muscle protein proteolysis observed in diseases such as cancerous cachexia, sepsis, serious trauma or muscular dystrophy.

Claims

1. A method for inhibiting the expression, the activity or a combination thereof, of at least one proteolytic enzyme that promotes muscle protein proteolysis comprising the step of administering a neutralizing antibody to an interleukin-6 receptor to a patient in need of the inhibition of the expression, activity or a combination thereof, of at least one proteolytic enzyme that promotes muscle protein proteolysis, wherein said neutralizing antibody inhibits the biological activity of interleukin-6 inhibiting binding between IL-6 and IL-6 receptor.

2. The method of claim 1, wherein said proteolytic enzyme is at least one of cathepsin, polyubiquitin or monoubiquitin.

3. The method of claim 2, wherein said proteolytic enzyme is at least one of Cathepsin B or Cathepsin L.

4. The method of claim 1, wherein said interleukin-6 receptor is a human interleukin-6 receptor.

5. The method of claim 1, wherein said antibody to said interleukin-6 receptor is a monoclonal antibody.

6. The method of claim 5, wherein said antibody to said interleukin-6 receptor is MR16-1.

7. The method of claim 5, wherein said antibody to said interleukin-6 receptor is PM-1.

8. The method of claim 5, wherein said antibody to said interleukin-6 receptor is a humanized PM-1.

9. The method of claim 2, wherein said antibody to said interleukin-6 receptor is a monoclonal antibody.

10. The method of claim 9, wherein said antibody to said interleukin-6 receptor is MR16-1.

11. The method of claim 9, wherein said antibody to said interleukin-6 receptor is PM-1.

12. The method of claim 9, wherein said antibody to said interleukin-6 receptor is a humanized PM-1.

13. The method of claim 1, wherein the expression, the activity or a combination thereof, of at least one proteolytic enzyme that promotes muscle protein proteolysis occurs in association with cancerous cachexia.